Health-Related Quality-of-Life Assessment in Patients With Cutaneous T-Cell Lymphoma

Marie-France Demierre, MD, FRCPC; Amy Tien, MD; Donald Miller, ScD

**Objective:** To measure and evaluate the health-related quality of life (HRQOL) in patients with cutaneous T-cell lymphoma (CTCL), a visible cutaneous malignancy that may have a profound effect on patients' lives.

**Design:** Monocenter, cross-sectional study.

**Setting:** The Skin Oncology Program, Department of Dermatology, and the Photopheresis Unit of Boston Medical Center.

**Patients:** A total of 22 adult patients with confirmed CTCL.

**Main Outcome Measures:** (1) Evaluation of general oncologic and skin disease-specific HRQOL using, respectively, the Functional Assessment of Cancer Therapy–General (FACT-G) and Skindex-29 profiles; (2) assessment of HRQOL association with disease stage (early stage, IA-IIA; late stage, IIB-IVB).

**Results:** Patients with more advanced CTCL stages reported more effects on general health (FACT-G), particularly in the physical, emotional, and functional domains ($P<.05$). Patients with early-stage CTCL reported better skin-specific HRQOL overall (Skindex-29; $P=.002$) and for each specific domain than did patients with late-stage disease. The Skindex-29 scales had high internal consistency, and the confirmatory factor structure was similar to that of previous studies.

**Conclusions:** The HRQOL of patients with CTCL can be evaluated using the Skindex-29 and FACT-G instruments. Patients with more advanced stages of CTCL had lower HRQOL scores.

Arch Dermatol. 2005;141:325-330

**Cutaneous T-cell lymphoma (CTCL) is a visible cutaneous malignancy that can cause significant morbidity and disfigurement and adversely affect patients' quality of life (QOL).** The most common type of primary skin lymphoma, CTCL has an estimated incidence of about 0.5 to 1 case per 100000. The most common forms, mycosis fungoides and its leukemic phase, Sézary syndrome, are generally chronic diseases. However, there is little available information on the experience of patients with mycosis fungoides or Sézary syndrome and how discrete aspects of their lives are affected by the disease.

**See also pages 305, 353, 361, 395, and 382**

Patients' perceptions of their health-related QOL (HRQOL) have become important measures of case mix and outcomes in dermatology and oncology. Health-related QOL is a multidimensional construct that includes the physical, functional, psychological, and social health and well-being of the individual. Several therapies are currently being investigated for CTCL, and so understanding the impact of CTCL and its treatments on patients' HRQOL has become important. Nonetheless, only a limited number of general HRQOL questionnaires have been used for CTCL, and no disease-specific HRQOL questionnaires have emerged to evaluate patients with CTCL. To evaluate the extent of CTCL and stage of disease on patients' HRQOL, we used 2 existing instruments: a general oncology HRQOL instrument, the Functional Assessment of Cancer Therapy–General (FACT-G), and a skin disease–specific HRQOL instrument, Skindex-29.

**METHODS**

**PATIENT SAMPLES**

Informed consent was obtained from 22 adult patients with a confirmed diagnosis of mycosis fungoides or Sézary syndrome. The study was approved by the institutional review board of Boston Medical Center. The sample included 10 patients with early-stage (IA-IIA) and 12 with late-stage (IIB-IVB) CTCL who were
referred to the Skin Oncology Program clinic or were undergoing treatment at Boston Medical Center for their disease. Demographic information, stage of disease, number of prior treatments, and number of comorbidities were recorded. Patients completed the questionnaires during their evaluation in the clinic or while undergoing treatment at Boston Medical Center.

HRQOL EVALUATION

General oncologic–specific HRQOL was measured using the FACT-G, version 4, a self-administered, 27-item questionnaire that has been used widely and is available in more than 40 languages. Through ongoing validation studies, the FACT-G has demonstrated sound psychometric properties to support its usefulness in evaluating HRQOL in cancer populations. It was chosen based on its prior successful use in studies of CTCL and other malignancies. The FACT-G instrument assesses 4 HRQOL domains: physical well-being (7 items); social and/or family well-being (7 items); emotional well-being (6 items); and functional well-being (7 items). Respondents use a 5-point Likert-type scale that rates the relevant domain from 0 (not at all) to 4 (very much). Possible scale scores (the sum of responses to the items included in the scale) range from 0 to 108, with a higher score indicating better HRQOL. The FACT-G has demonstrated both discriminant and convergent validity, with test-retest correlations ranging from 0.82 to 0.92 for each FACT-G subscale. The FACT-G can be completed in 5 to 10 minutes.

Skin disease–specific HRQOL was measured using the Skindex-29, a validated, self-administered, 29-item questionnaire. Results of the Skindex-29 are reported as 3 scale scores assessing emotions, physical symptoms, and functioning. Scale scores are the means of responses to the items included in the scale. Possible scale scores range from 0 to 108, with a higher score indicating worse HRQOL. The Skindex-29 has demonstrated both discriminant and convergent validity with test-retest correlation ranging from 0.88 to 0.92. Completion of the Skindex-29 takes 5 minutes. Scoring of FACT-G and Skindex-29 scales was performed as previously described.

STATISTICAL ANALYSIS

Scale scores computed for each patient were summarized as means (SDs) overall and in subsets of patients defined by sex, age, and stage of disease. Differences between groups were tested using \( t \) tests and general linear regression. Psychometric properties of the questionnaires were evaluated using confirmatory factor analysis, with matrix structures specified based on previously published reports. Confirmation was based on loading of individual items to prescribed factors. Higher factor loading scores indicate that item responses are more strongly correlated with other items in the factor. For presentation purposes, score values were multiplied by 100, and a minimum value of 50 was used as the criterion of significance. This analysis was conducted using Proc Calis in SAS 8.2 (SAS Institute Inc, Cary, NC). Internal consistency reliability of scales was assessed using Cronbach’s coefficients.

The 22 patients with CTCL ranged in age from 32 to 81 years (mean age, 63.1 years) (Table 1). There were equal numbers of male and female patients, and most were white. All patients had received prior treatment (mean number of prior therapies, 2.5; Table 2). Sixteen (73%) of the patients had at least 1 comorbidity. Common comorbidities included coronary artery disease, hypertension, hypercholesterolemia, diabetes, and peripheral vascular disease; less common comorbidities included history of uterine cancer, erectile dysfunction, urinary incontinence, osteoarthritis, congenital optical blindness, B-cell chronic lymphocytic leukemia, and nonmelanoma skin cancers.

The FACT-G mean scale scores for patients with CTCL are listed in Table 3. Mean (SD) scores ranged from 17.9 (5.9) to 22.7 (5.7). For comparison purposes, Table 3 also includes published FACT-G mean scale scores for patients with nonmelanoma cervicofacial skin cancer (NMSC). For all 4 scales, mean scores were lower in our patients with CTCL.

Skindex-29 mean scale scores for patients with CTCL are listed in Table 4. Mean scale scores ranged from 19.1 to 24.2, indicating some effects of the skin disease on HRQOL.

---

**Table 1. Patient Demographic and Disease Characteristics**

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>No. of Patients* (N = 22)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex</td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>11</td>
</tr>
<tr>
<td>Female</td>
<td>11</td>
</tr>
<tr>
<td>Ethnicity</td>
<td></td>
</tr>
<tr>
<td>White</td>
<td>29</td>
</tr>
<tr>
<td>African American</td>
<td>1</td>
</tr>
<tr>
<td>Asian</td>
<td>1</td>
</tr>
<tr>
<td>Disease stage</td>
<td></td>
</tr>
<tr>
<td>IA-IIB</td>
<td>10</td>
</tr>
<tr>
<td>IIB-IVA</td>
<td>12</td>
</tr>
<tr>
<td>IVB</td>
<td>0</td>
</tr>
<tr>
<td>No. of comorbidities</td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>6</td>
</tr>
<tr>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>2</td>
<td>7</td>
</tr>
<tr>
<td>&gt;3</td>
<td>7</td>
</tr>
</tbody>
</table>

*Mean patient age, 63.1 years; age range, 32 to 81 years.

---

**Table 2. Prior Therapies Received by Study Patients***

<table>
<thead>
<tr>
<th>No. of Prior Therapies</th>
<th>No. of Patients</th>
<th>Type of Therapy†</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>6</td>
<td>X</td>
</tr>
<tr>
<td>2</td>
<td>3</td>
<td>XX</td>
</tr>
<tr>
<td>3</td>
<td>4</td>
<td>X</td>
</tr>
<tr>
<td>4</td>
<td>1</td>
<td>X</td>
</tr>
<tr>
<td>≥5</td>
<td>1</td>
<td>XXX</td>
</tr>
<tr>
<td>2</td>
<td>2</td>
<td>XXX</td>
</tr>
<tr>
<td>2</td>
<td>2</td>
<td>XXX</td>
</tr>
</tbody>
</table>

*Prior topical therapies included steroids, chemotherapy, and bexarotene; prior systemic therapies included phototherapy (UV-B, narrowband UV-B, and psoralen plus UV-A), local radiation, total skin electron beam radiation, oral bexarotene, subcutaneous interferon alfa, subcutaneous interleukin 2, and extracorporeal photopheresis.

†Each X indicates 1 therapy.
EFFECTS OF EARLY- VS LATE-STAGE CTCL ON HRQOL

Patients with late-stage CTCL (IB-IIA) reported lower FACT-G scores than patients with early-stage disease (IA-IIA) overall and across all domains (Table 5). Statistically significant differences (P<.05) were observed for all individual scales except social/family well-being.

Similar results were found for Skindex-29. Patients with late-stage CTCL had significantly higher (worse) mean scores overall and across all scales than did patients with early-stage disease.

PSYCHOMETRIC ANALYSIS

The results from confirmatory factor analysis of the Skindex-29 are listed in Table 6. Most items loaded appropriately to the 3 scales (emotions, symptoms, and functioning) previously defined and described.14 In only a few instances were factor-loading scores in a scale lower than 50 (eg, “worry about getting scars” failed to load on the emotions scale as expected but loaded on functioning instead) or were items split between scales with factor-loading scores higher than 50 for 2 factors (eg, “condition affects my desire to be with people” loaded on both the emotions and functioning scales). Otherwise, items loaded appropriately, and the questionnaire appeared to provide reliable measures of emotional, symptomatic, and functional domains of HRQOL in patients with CTCL. The internal consistency reliability of the scales as indicated by the Cronbach α coefficients ranged from 0.89 to 0.95.

COMMENT

Cutaneous T-cell lymphoma is a disease with visible manifestations that may include patches, plaques, tumors, hair loss, keratoderma, fissures, and symptoms of pruritus and pain. These signs, as well as an increasing risk of death with worsening stage, would be expected to have important effects on patients’ QOL. This includes effects on emotions (eg, fear of death, embarrassment from skin condition, anger, frustration), physical functioning (eg, ability to work or do hobbies), and social well-being (eg, ability to interact with others or desire to be with others). Even without increased mortality risk, patients with the earliest stage of CTCL, stage IA, might have impaired HRQOL. For example, a patient with stage IA disease commented on how the visible nature of the skin lesions prevented her from going to the beach with her family. These and other impairments in HRQOL would be expected to increase with increasing stage of disease.

In our study, we examined general oncologic health and skin-specific HRQOL in a representative sample of patients with CTCL seen at our center. We found relatively poor HRQOL associated with the disease, with the lowest levels in patients with the most advanced disease.

Patients with CTCL reported low scale scores (impaired HRQOL) in all 4 FACT-G subscales (physical, social/family, emotional, and functional well-being). These values were lower than those reported by patients with high-risk NMSC.19 The population of 121 patients with high-risk NMSC (median age, 63 years) consisted of patients referred to a tertiary care surgery clinic for removal of a high-risk NMSC lesion (eg, tumor diameter, >2 cm; tumor of long duration; and/or tumor arising within the high-risk facial zone). Although variations in sociodemographic characteristics or comorbidities between the 2 patient groups may explain part or all of the observed differences, this finding suggests that patients with CTCL have relatively poor HRQOL, as measured with FACT-G.

For skin disease–specific HRQOL measured with Skindex-29, patients with CTCL reported decrements of HRQOL in all 3 dimensions (emotional, symptoms, and functioning). The observed mean scale scores (emotions, 23.9; symptoms, 19.1; and functioning, 24.2; Table 4) appear to be considerably higher than the published mean scale scores for 107 healthy volunteers who denied skin problems (emotions, 9.2; symptoms, 13.8; and functioning, 3.7).23 Several studies have highlighted the impact of psoriasis on HRQOL.24,25 In the present study, overall, the impact of CTCL on functioning (mean scale score, 24) seemed to be similar to that reported for patients with psoriasis assessed with Skindex-29 (mean scale score, 23).24 Although the effect on emotions and symptoms well-being appeared to be somewhat less. However, part or all of these differences may be related to other differences between psoriasis and CTCL patient populations. For example, in the present study, the mean age of patients with CTCL was 63.1 years, considerably older than the mean age of 47 years reported in 1 series of patients with psoriasis.20 Furthermore, QOL...
Health-related QOL was related to CTCL stage. The FACT-G scores were lower (worse) and Skindex-29 scores were higher (worse) in patients with late-stage disease than in those with early-stage disease. This was evident across all scales of the 2 instruments. These results are consistent with expectations in that patients with late-stage CTCL generally have more severe symptoms (eg, pruritus and pain) and face higher risks of debilitating disease and death than do patients with early-stage disease. This indicates face validity for both FACT-G and Skindex-29 measures and suggests that they are appropriate instruments for measuring HRQOL in CTCL. The completion time for the 2 questionnaires was not burdensome: it took no more than 15 minutes.

Skindex-29 showed good psychometric properties with high internal consistency, reliability, and factor structure, similar to its performance in previous reports. The few aberrant items that showed low factor-loading scores or that split between scales were questions that also showed the lowest scores in the published analyses. This questionnaire appears to measure emotional, symptomatic, and functional impacts of CTCL, as originally defined in the development of Skindex-29, with reasonably good accuracy and precision.

There are several limitations that should be kept in mind. This study was limited to a single tertiary referral center, and the results might not be generalizable to all patients with CTCL. In particular, our sample included mostly white patients, whereas the national data indicate a higher incidence rate among African Americans than among whites (1.6; 95% confidence interval, 1.3-1.8).

It is also possible that our patients with CTCL were referred to our tertiary referral center because they felt a greater impact of CTCL on their HRQOL. Alternatively, since most of our patients completed the questionnaires either after their evaluation or during treatment, this timing might have minimized the impact on HRQOL, especially in those with early-stage disease vs more advanced disease (ie, those with a better prognosis may have been reassured by their visit or treatment) and thus magnified the difference between early-stage and late-stage disease. In addition, one cannot exclude the possibility that completing the HRQOL instruments after consultation in the Skin Oncology Program clinics or while receiving therapy influenced the responses of all patients, overall minimizing the impact of CTCL on their HRQOL.

Future studies should ensure that the administration of questionnaires is done in a consistent manner, eg, prior to a clinic visit or to receiving therapy.

The sample size of only 22 patients was another limitation. A larger patient population involving multiple centers would provide a more representative sample to evaluate the impact of CTCL on HRQOL and increase power to detect differences.

Another limitation is that the study was cross-sectional. We evaluated QOL at only 1 time point. The study did not observe patients prospectively to evaluate disease impact on aspects of life over time. Future studies should evaluate responsiveness to change of both instruments in patients with CTCL.

We are aware of only 3 studies that have evaluated HRQOL of patients with CTCL (Table 7). The first study was a phase 3 study of denileukin diftitox (ONTAK; Ligand Pharmaceuticals, San Diego, Calif) in 71 patients with stage IB-IVA disease, where FACT-G (third version) was the only HRQOL instrument administered at baseline and after each course of therapy. The study showed a correlation between clinical response and improved HRQOL as measured by FACT-G. The second study, a multicenter study of oral bexarotene in 94 patients with stage IB-IVB disease, used the general status HRQOL questionnaire. Baseline scores were reportedly high and did not substantially change during the study. In the third study, Bisaccia et al described the use of a 20-item, CTCL-
There were no data on reliability, test-retest reliability, in studies of investigational agents, researchers should also evaluate CTCL HRQOL with the SF-36. The combination of a generic and a dermatology-specific questionnaire has been recommended for psoriasis research. Furthermore, on the basis of psychometric data, Skindex-29 was found to be the most valuable dermatology-specific questionnaire for psoriasis research. While the present study did not include a generic questionnaire such as the SF-36 (Medical Outcomes Study Short-Form Health Survey), future studies should also evaluate CTCL HRQOL with the SF-36 to better assess the extent of impairment compared with the general population.

In conclusion, we have demonstrated that HRQOL can be assessed in patients with CTCL using both FACT-G and Skindex-29. Our study findings indicate that patients with advanced-stage disease report a greater impact of CTCL on their HRQOL than do those with earlier stages. Future studies should, in addition to including the SF-36, evaluate responsiveness to change with FACT-G and Skindex-29. Since CTCL remains a relatively incurable disease, we believe that in studies of investigational agents, researchers should also assess patients’ HRQOL. Focusing our efforts on improving not only the manifestations of CTCL but also patients’ HRQOL should translate into improvements that are meaningful to them.

The present study is the first to our knowledge to report on discrete aspects of the HRQOL of patients with CTCL as measured by both general-oncologic and skin-specific HRQOL questionnaires. The importance of combining both instruments in assessing the extent of HRQOL impairment is highlighted by the recent literature in psoriasis research. The combination of a generic and a dermatology-specific questionnaire has been recommended for psoriasis research. Furthermore, on the basis of psychometric data, Skindex-29 was found to be the most valuable dermatology-specific questionnaire for psoriasis research. While the present study did not include a generic questionnaire such as the SF-36 (Medical Outcomes Study Short-Form Health Survey), future studies should also evaluate CTCL HRQOL with the SF-36 to better assess the extent of impairment compared with the general population.

In conclusion, we have demonstrated that HRQOL can be assessed in patients with CTCL using both FACT-G and Skindex-29. Our study findings indicate that patients with advanced-stage disease report a greater impact of CTCL on their HRQOL than do those with earlier stages. Future studies should, in addition to including the SF-36, evaluate responsiveness to change with FACT-G and Skindex-29. Since CTCL remains a relatively incurable disease, we believe that in studies of investigational agents, researchers should also assess patients’ HRQOL. Focusing our efforts on improving not only the manifestations of CTCL but also patients’ HRQOL should translate into improvements that are meaningful to them.

### Table 6. Confirmatory Factor Analysis for Skindex-29 Among 22 Patients With CTCL

<table>
<thead>
<tr>
<th>Confirmatory Factor Analysis</th>
<th>Emotions</th>
<th>Symptoms</th>
<th>Functioning</th>
</tr>
</thead>
<tbody>
<tr>
<td>I worry that my skin condition may be serious.</td>
<td>56*</td>
<td>49</td>
<td>36</td>
</tr>
<tr>
<td>My skin condition makes me feel depressed.</td>
<td>77*</td>
<td>22</td>
<td>35</td>
</tr>
<tr>
<td>I worry about getting scars from my skin condition.</td>
<td>17</td>
<td>1</td>
<td>58*</td>
</tr>
<tr>
<td>I am ashamed of my skin condition.</td>
<td>76*</td>
<td>23</td>
<td>44</td>
</tr>
<tr>
<td>I worry that my skin condition may get worse.</td>
<td>82*</td>
<td>9</td>
<td>24</td>
</tr>
<tr>
<td>I am angry about my skin condition.</td>
<td>74*</td>
<td>12</td>
<td>41</td>
</tr>
<tr>
<td>I am embarrassed by my skin condition.</td>
<td>74*</td>
<td>15</td>
<td>49</td>
</tr>
<tr>
<td>I am frustrated by my skin condition.</td>
<td>81*</td>
<td>23</td>
<td>37</td>
</tr>
<tr>
<td>I am humiliated by my skin condition.</td>
<td>72*</td>
<td>21</td>
<td>42</td>
</tr>
<tr>
<td>I am annoyed by my skin condition.</td>
<td>76*</td>
<td>31</td>
<td>29</td>
</tr>
<tr>
<td>My skin hurts.</td>
<td>–1</td>
<td>65*</td>
<td>50*</td>
</tr>
<tr>
<td>My skin condition burns or stings.</td>
<td>18</td>
<td>55*</td>
<td>38</td>
</tr>
<tr>
<td>My skin itches.</td>
<td>–2</td>
<td>72*</td>
<td>29</td>
</tr>
<tr>
<td>Water bothers my skin condition (bathing, washing hands).</td>
<td>59*</td>
<td>54*</td>
<td>31</td>
</tr>
<tr>
<td>My skin is irritated.</td>
<td>7</td>
<td>82*</td>
<td>12</td>
</tr>
<tr>
<td>My skin condition bleeds.</td>
<td>27</td>
<td>64*</td>
<td>37</td>
</tr>
<tr>
<td>My skin condition affects how well I sleep.</td>
<td>–3</td>
<td>54*</td>
<td>30</td>
</tr>
<tr>
<td>My skin condition affects how close I can be with those I love.</td>
<td>27</td>
<td>65*</td>
<td>23</td>
</tr>
<tr>
<td>My skin condition makes it hard to do work or do hobbies.</td>
<td>61*</td>
<td>49</td>
<td>37</td>
</tr>
<tr>
<td>My skin condition affects my social life.</td>
<td>38</td>
<td>32</td>
<td>62*</td>
</tr>
<tr>
<td>I tend to stay at home because of my skin condition.</td>
<td>51*</td>
<td>39</td>
<td>57*</td>
</tr>
<tr>
<td>My skin condition affects how close I can be with those I love.</td>
<td>19</td>
<td>20</td>
<td>86*</td>
</tr>
<tr>
<td>I tend to do things by myself because of my skin condition.</td>
<td>20</td>
<td>49</td>
<td>59*</td>
</tr>
<tr>
<td>My skin condition makes showing affection difficult.</td>
<td>24</td>
<td>–16</td>
<td>84*</td>
</tr>
<tr>
<td>My skin condition affects my interactions with others.</td>
<td>46</td>
<td>38</td>
<td>58*</td>
</tr>
<tr>
<td>My skin condition is a problem with the people I love.</td>
<td>33</td>
<td>–10</td>
<td>77*</td>
</tr>
<tr>
<td>My skin condition affects my desire to be with people.</td>
<td>58*</td>
<td>28</td>
<td>57*</td>
</tr>
<tr>
<td>My skin condition interferes with my sex life.</td>
<td>21</td>
<td>–17</td>
<td>74*</td>
</tr>
<tr>
<td>My skin condition makes me tired.</td>
<td>28</td>
<td>20</td>
<td>58*</td>
</tr>
</tbody>
</table>

Cronbach α coefficient: 0.951 0.887 0.935

Abbreviation: CTCL, cutaneous T-cell lymphoma.
*Factor loading score of 50 or higher.

### Table 7. Comparison of HRQOL Instruments Used in Acne Vulgaris, Psoriasis, and CTCL

<table>
<thead>
<tr>
<th>Source</th>
<th>HRQOL Instrument</th>
<th>Medical Condition Evaluated</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lasek and Ohren</td>
<td>Skindex-29</td>
<td>Acne vulgaris</td>
</tr>
<tr>
<td>Weiss et al</td>
<td>Patients general perception of their psoriasis</td>
<td>Psoriasis</td>
</tr>
<tr>
<td>Olsen et al</td>
<td>FACT-G (3rd version)</td>
<td>CTCL</td>
</tr>
<tr>
<td>Bisaccia et al</td>
<td>A 20-item CTCL-specific HRQOL questionnaire</td>
<td>CTCL</td>
</tr>
</tbody>
</table>

Abbreviations: CTCL, cutaneous T-cell lymphoma; FACT-G, Functional Assessment of Cancer Therapy–General; HRQOL, health-related quality of life; SF-36, Medical Outcomes Study Short Form Health Survey.
Accepted for Publication: June 11, 2004.  
Correspondence: Marie-France Demierre, MD, FRCP,  
Boston University School of Medicine, Skin Oncology  
Program, Boston Medical Center, 720 Harrison Ave,  
DOB 801A, Boston, MA 02118 (mariefrance.demierre@bmc.org).  
Funding/Support: This study was supported in part by the  
Carl J. Herzog Foundation, Exeter, NH (Dr Demierre).  
Acknowledgment: We thank David Cella, MD, for his per-
mission to use FACT-G (version 4) and Mary-Margaret  
Chren, MD, for her permission to use Skindex-29 and for  
her kind encouragement.

REFERENCES

1. Demierre MF, Kim YH, Zachariae HS. Prognosis, clinical outcomes and quality  
17:1485-1507.


3. Finlay AY. Quality of life measurement in dermatology: a practical guide. Br J  

4. Chren MM. Understanding research about quality of life and other health outcomes.  

5. American Society of Clinical Oncology. Outcomes of cancer treatment for tech-
ology assessment and cancer treatment guidelines. J Clin Oncol. 1996;14:  
671-679.

the U.S. Food and Drug Administration perspective. J Natl Cancer Inst Monogr.  


10. Demierre MF, Vachon L, Ho V, et al. Phase 1/2 pilot study of methotrexate-
laurocapram topical gel for the treatment of patients with early-stage mycosis fungoides.  


scale: development and validation of the general measure. J Clin Oncol. 1993; 
11:570-579.

14. Chren MM. Quality of care in dermatology: the state of (measuring) the art. Arch  

ment of Cancer Therapy-Colorectal (FACT-C) quality of life measurement instrument.  

15:974-986.

17. Brenner E, Duivc M, Frankel A, et al. Pivotal phase III trial of two dose levels of  

patients with hepatobiliary cancers: the functional assessment of cancer therapy-

19. Rhee JS, Lobener FR, Matthews BA, et al. Quality of life assessment in nonmela-

Assessment of Cancer Therapy (FACT) quality of life measurement system. Qual  

generic and a disease-specific instrument to measure quality of life in patients  

capability of a refined version of Skindex, a quality-of-life instrument for pa-

23. Lasek RJ, Chren MM. Acne vulgaris and the quality of life of adult dermatology  


health-related quality of life among Norwegian adult patients with psoriasis  

27. Cella D, Chang CH, Lai JS, et al. Advances in quality of life measurements in on-

28. Weinstock MA, Gardstein B. Twenty-year trends in the reported incidence of my-
1244.

29. Spitzer WD, Dobson AJ, Hall J, et al. Measuring the quality of life of cancer pa-
tients: a concise QL-index for use by physicians. J Chronic Dis. 1981;34:585- 
597.

of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase  

(Targretin capsules) for the treatment of refractory or persistent early-stage cu-

or with adjuvant therapy in the treatment of cutaneous T-cell lymphoma: a 9-year 
retrospective study at a single institution. J Am Acad Dermatol. 2000;43:263- 
271.

questionnaires for psoriasis research: a systematic literature review. Arch Dermatol.  
2002;138:1221-1227.

34. Brazier JE, Harper R, Jones NM, et al. Validating the SF-36 health survey ques-

35. Jenkinson C, Wright L, Coulter A. Criterion validity and reliability of the SF-36 in 

36. McHorney CA, Ware JE Jr, Raczek AE. The MOS 36-item Short-Form Health  
Survey (SF-36), II: conceptual framework and item selection. Med Care. 1993;31:247- 
263.

37. McHorney CA, Ware JE Jr, Raczek AE. The MOS 36-item Short-Form Health  

38. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF- 

39. Ware JE Jr, Kosinski M, Bayless MS, et al. Comparison of methods for the scor-
ing and statistical analysis of SF-36 health profile and summary measures: sum-
mary of results from the Medical Outcomes Study. Med Care. 1993;31:AS264-
AS279.